News sentiment analysis powered by sentiment-insight.com
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
Pieris Pharmaceuticals (NASDAQ:PIRS) has a negative free cash flow of US$47m. Its cash burn is 212% of its US$22m market capitalisation. This suggests the company may have some funding difficulties, and we'd be very wary of the stock. We think its revenue growth was reassuring, while its cash burn relative to its market cap has us a bit worried.
Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis Pieris Pharmaceuticals Inc (NASDAQ:PIRS) recorded a gain of 12.73% in a day and a 3-month decrease of 44.32%. According to its GF Value, the fair valuation of the stock is $1.62. The company's revenues and earnings have been on a downward trend over the past five years.
Why Pieris Pharmaceuticals Shares Shooting Higher Today? Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company provided a strategic update. Company says the update follows recent events that have impacted its inhaled respiratory franchise.
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate Pieris Pharmaceuticals (NASDAQ:PIRS) burned through US$49m in the last year. This is the annual rate at which an unprofitable company spends cash to fund its growth. It has a market capitalisation of US$75m, so its cash burn equates to about 66% of its market value. That's very high expenditure relative to the company's size, suggesting it is a high risk stock.
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shares are up 4.8% to US$0.86 in the past week. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business. It will be interesting to see if this downgrade motivates investors to start selling their holdings.
Pieris Pharmaceuticals: Q1 Earnings Snapshot Pieris Pharmaceuticals Inc. (PIRS) reported a loss of $13.2 million in its first quarter. The biopharmaceutical company posted revenue of $1.9 million in the period.
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript March 29, 2023. Steve Yoder, President and CEO, will provide a corporate overview and outlook on our pipeline. Hitto Kaufmann, Chief Scientific Officer; Shane Olwill, Chief Development Officer; and Mary Fitzgerald, Vice President, Project Leader Elarekibep, will be available for Q&A.
Pieris Pharmaceuticals (NASDAQ:PIRS) shareholders have endured a 81% loss from investing in the stock five years ago Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shareholders will doubtless be very grateful to see the share price up 72% in the last quarter. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. The million dollar question is whether the company can justify a long term recovery.
Sign Up
